AI is increasingly being used to de-risk both therapeutic development and companion diagnostic pathways, with digital pathology and model-driven analyses moving closer to trial decision points. The coverage emphasizes faster translation from pathology images to actionable signals that can guide patient stratification and development risk. In parallel, Roche’s PathAI acquisition reflects how major biopharma is consolidating AI pathology assets to standardize image analysis across sites and studies. Together, the developments point to digital pathology as a recurring investment target rather than a peripheral technology. For biotech teams planning trials, the key shift is from offline analysis to workflow integration—where AI outputs influence go/no-go, dose decisions, and biomarker confirmation timelines.